Telix Pharmaceuticals

Telix Pharmaceuticals ROE

The Return on Equity (ROE) of Telix Pharmaceuticals (TLX.AX) as of Nov 19, 2026 is -1.72 %. In the previous year, Return on Equity (ROE) was 9.54 % — a change of -117.97% (lower).

ROE

-1.72 %

YoY

-117.97%

Last updated:

In 2025, Telix Pharmaceuticals's return on equity (ROE) was -1.72 %, a -117.97% increase from the 9.54 % ROE in the previous year.

The Telix Pharmaceuticals ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-26.14 USD
Jan 1, 2019
-39.76 USD
Jan 1, 2020
-56.81 USD
Jan 1, 2021
-3,730.77 USD
Jan 1, 2022
-130.09 USD
Jan 1, 2023
4.10 USD
Jan 1, 2024
9.54 USD
Jan 1, 2025
-1.72 USD
The Telix Pharmaceuticals ROE history
YEARROEYoY
-1.72 %-117.97%
9.54 %+132.81%
4.10 %-103.15%
-130.09 %-96.51%
-3,730.77 %+6,467.39%
-56.81 %+42.86%
-39.76 %+52.11%
-26.14 %+102.06%
-12.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

ROE Details

Decoding Telix Pharmaceuticals's Return on Equity (ROE)

Telix Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Telix Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Telix Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Telix Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Telix Pharmaceuticals stock

Return on Equity (ROE) of Telix Pharmaceuticals is -1.72 % in 2025.

Return on Equity (ROE) of Telix Pharmaceuticals changed from 9.54 % to -1.72 %, representing a -117.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals